Generaal de Wittelaan 11 B
32 1 563 26 00
Impiegati a tempo pieno: 526
|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Jean-Marc Roelandt||Chief Financial Officer||N/D||N/D||1965|
|Mr. Piet Houwen||Chief Operating Officer||N/D||N/D||1968|
|Mr. Roger Moody||Chief Exec. Officer||N/D||N/D||N/D|
|Mr. Benoit Devogelaere||Chief Technology Officer||N/D||N/D||1981|
|Mr. Geert Maertens Ph.D.||Chairman of Scientific Advisory Board & Chief Scientific Officer||N/D||N/D||N/D|
|Renate Degrave||Head of IR & Corp. Communications||N/D||N/D||N/D|
|Ms. Susy Spruyt||Head of People & Organization||N/D||N/D||1968|
|Dr. Erwin Sablon||Head of R&D and Alliance Management||N/D||N/D||1965|
|Mr. Reginald Van Genechten||Head of Manufacturing & Supply Chain||N/D||N/D||1966|
|Mr. Erik Vossenaar||VP of Bus. Devel.||N/D||N/D||1973|
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.
L'ISS Governance QualityScore di Biocartis Group NV al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.